Home ›
Acute Lymphoblastic (ALL) Leukemia Trials ›
NCT06712121
Venetoclax and Decitabine in R/R T-ALL
The goal of this phase 2 clinical trial is to test the efficacy of decitabine and venetoclax combination chemotherapy in relapsed or refractory adult T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma.
This study use a modified regimen of decitabine and venetoclax.
Trial Details
NCT ID NCT06712121
Phase PHASE2
Sponsor Seoul National University Hospital
Status RECRUITING
Cancer Type Acute Lymphoblastic (ALL) Leukemia
Interventions decitabine plus venetoclax
Locations (sample) Seongnam-si, South Korea|37.43861,127.13778 Seoul, South Korea|37.566,126.9784 Seoul, South Korea|37.566,126.9784
Key Eligibility Criteria
Adults aged 19 years or older but less than 80 years Eastern Cooperative Oncology Group Performance Score (ECOG PS) ≤ 2 Confirmed diagnosis of T-cell lymphoblastic leukemia/lymphoma according to the 2016 World Health Organization criteria, with relapse or failure to … Patients with peripheral blood leukocytes \<50,000/uL (reducing white blood cell count through hydroxyurea or leukapheresis prior to trial enrol…
For full eligibility, visit ClinicalTrials.gov .